Comirnaty Uniunea Europeană - română - EMA (European Medicines Agency)

comirnaty

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaccinuri - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. utilizarea acestui vaccin ar trebui să fie în conformitate cu recomandările oficiale.

Insuman Uniunea Europeană - română - EMA (European Medicines Agency)

insuman

sanofi-aventis deutschland gmbh - insulin human - diabetul zaharat - medicamente utilizate în diabet - diabet zaharat în care este necesară tratamentul cu insulină. insuman rapid este de asemenea potrivit pentru tratamentul hyperglycaemic comă şi cetoacidoza, precum şi pentru realizarea pre-, intra - şi stabilizare postoperatorie la pacienţii cu diabet zaharat.

CEFTAZIDIMA APTAPHARMA 1 g România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

ceftazidima aptapharma 1 g

acs dobfar s.p.a. - italia - ceftazidimum - pulb. pt. sol. inj./perf. - 1g - alte antibiotice betalactamice cefalosporine de generatia a - iii-a

CEFTAZIDIMA APTAPHARMA 2 g România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

ceftazidima aptapharma 2 g

acs dobfar s.p.a. - italia - ceftazidimum - pulb. pt. sol. inj./perf.  - 2g - alte antibiotice betalactamice cefalosporine de generatia a - iii-a

Actilyse 50 mg pulbere şi solvent pentru soluţie injectabilă/perfuzabilă Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

actilyse 50 mg pulbere şi solvent pentru soluţie injectabilă/perfuzabilă

boehringer ingelheim international gmbh - alteplasum - pulbere şi solvent pentru soluţie injectabilă/perfuzabilă - 50 mg

Doribax Uniunea Europeană - română - EMA (European Medicines Agency)

doribax

janssen-cilag international nv - doripenemul - pneumonia, ventilator-associated; pneumonia, bacterial; urinary tract infections; bacterial infections; cross infection - antibacteriene pentru uz sistemic, - doribax este indicat pentru tratamentul următoarelor infecții la adulți:pneumonie nosocomială (inclusiv ventilator-associated pneumonia);infecții intra-abdominale complicate;infecții complicate ale tractului urinar. trebuie luate în considerare ghidurile oficiale referitoare la utilizarea adecvată a medicamentelor antibacteriene.

ACTILYSE 50 mg România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

actilyse 50 mg

boehringer ingelheim pharma gmbh & co. kg - germania - alteplasum - pulb.+solv. pt. sol. inj./perf. - 50mg - antitrombotice enzime